Proposal for Objective Evaluation of the Performance of Various Functional APC-resistance Tests in Genotyped Patients

Summary

The aim of the present study was to evaluate the relative performance of five screening methods for APC resistance caused by the factor V:Q⁵⁰⁶ mutation: the original method Coatest® APC™ Resistance Chromogenix, a modified method using the same reagents but a predilution 1+4 of the plasma in a factor V deficient plasma from Stago (Stago deficient V) or from Chromogenix (V-DEF Plasma), the Coatest® APC™ Resistance V (Chromogenix), and Accelerimat™ from bioMérieux. Normalization was done against a pool of normal plasmas for the methods from Chromogenix. The study included 350 subjects, 219 were genotyped (174 FV:R⁵⁰⁶R, 42 FV:Q⁵⁰⁶R, 3 FV:Q⁵⁰⁶Q) and most of them were assessed by more than one method. Uncertainty in predicting the FV genotype was evaluated by statistical analysis, which provided a way to quantitate the performance of the different diagnostic approaches. Performance of each test was evaluated by its sensitivity, specificity, R.O.C. curves, positive and negative likelihood ratios (LR), and the overall performance was determined by two parameters derived from the LR curves : the maximum LR value obtained at the crossover of the two curves, and the distance between the two curves for LR = 10. Coatest® APC™ Resistance V and Accelerimat™ were proven to be the methods most able to discriminate for factor V:Q⁵⁰⁶, while normalization was not shown to improve the screening performance. The original method from Chromogenix was confirmed to undergo many influences (factor XII, PAI-1, thrombin- antithrombin complexes, antithrombin III, hematocrit). Although a very good improvement was provided by the newest methods, they were shown to be influenced by protein S and/or factor V levels in the sample plasma.

• References

• 1 Freyburger G, Nabera C, Bilhou-Javorschi S, Dief S, Lere-Labrouche S, beller MJ, Boisseau MR. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost 1996; 75: 460-465
• 2 Koster T, Rosendaal FR, De RondeH, Brië E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C : Leiden Thrombophilia study. Lancet 1993; 432: 1503-1506
• 3 Cumming AM, Tait RC, Fildes IS, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-727
• 4 Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulant. Thromb Haemost 1995; 74: 797-798
• 5 Rao AK, Elliott D, Stadnicki A, DeLaCadena R, Sherry S. High levels of plasma factor VIIIc impair anticoagulant response to activated protein C. Thromb Haemost 1995; 73: 1126
• 6 Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163
• 7 Trossaërt M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709
• 8 Ausseil F, Alhenc-Gelas M, Pittet JL, Dupuy G, Aiach M. A new chrono- metric assay for the research of factor V Leiden evaluated using venous thrombotic patients, patients under AVK treatment and normal controls. Thromb Haemost 1995; 73: 1362
• 9 Leroy-Matheron C, Gouault-Heilman M. Evaluation of a new chronometric assay (Accelerimat, bioMérieux) for the factor V Leiden-dependent activated protein C (APC) resistance. Haemostasis 1996; 26 (Suppl. 03) 212
• 10 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde, van derVeidenPJ, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 11 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738
• 12 Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwartz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76: 208-214
• 13 Rosen S, Johansson K, Lindberg K, Dahlbäck B. (for the APC resistance group) Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
• 14 Trossaërt M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75: 521-522
• 15 Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and healthy controls. Thromb Haemost 1997; 77: 332-335
• 16 Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV:Q⁵⁰⁶ mutation-Evaluation of thirtee plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-439
• 17 Van derBomJG, Bots ML, Haverkate F, Slagboom E, Meijer P, de JongPTVM, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-269
• 18 Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res 1996; 82: 235-244
• 19 Fisher M, Fernandez JA, Ameriso SF, Xie D, Paganini-Gruber A, Hill A, Griffin JH. Activated protein C resistance in ischemic stroke not due to factor V arginine506>glutamine mutation. Stroke 1996; 27: 1163-1166